CAS: 60-27-5; 2-Amino-1-Methyl-1,5-Dihydro-4H-Imidazol-4-One

上下游产品

sarcosine guanidine hydrogen carbonate Sarcosine ethyl ester CYANAMID(1-methylguanidino)glyoxylic acid Creatinine 2-acetylamino-5-(4-chloro-benzylidene)-1-methyl-1,5-dihydro-imidazol-4-one 2-acetylamino-5-(2-chloro-benzylidene)-1-methyl-1,5-dihydro-imidazol-4-one

肌酸置于盐酸体系中,用 水 作为反应溶剂,化学反应 1656.0H,反应生成 肌酸酐
参考文献:Bstfa对肌酐和肌酸衍生化的gc-Ms研究及其在人体尿液中的测定
标题:Bstfa对肌酐和肌酸衍生化的gc-Ms研究及其在人体尿液中的测定
摘要:考虑到其相对恒定的尿排泄率,肌酐(2-氨基-1-甲基-5 H尿中的-Imidazol-4-One,Mw 113.1)是有用的内源性生化参数,可校正多种内源性和外源性物质的尿排泄率.通过基于气相色谱(gc)的方法可靠地测量肌酐需要对其胺基和酮基进行衍生化.肌酐与其开放式肌酸(甲基胍基乙酸,Mw 131.1)处于平衡状态,肌酸具有胍基和羧基.肌酸酐和肌酸的三甲基甲硅烷基化和三氟乙酰化是人类血清中使用火焰或电子电离进行gc-质谱(ms)分析的最古老的衍生化方法.我们对肌酸酐的衍生化(d进行gc-Ms研究0-Creatinine),[Methylo-2 ħ 3]肌酐(d 3-Creatinine,内标),肌酸(d 0-肌酸)与ñ,ö-双在没有(三甲基硅烷基)三氟乙酰胺使用标准衍生化条件(bstfa)(60分钟,60oc),但任何基础.反应产物的特征在于负离子化学电离(nici)和正离子
DOI:10.3390/molecules26113206

专利信息

专利号:WO-2006046949-A1
优先权日:2004-10-22
标 题 :SYNTHESIS AND ANTIMALARIAL ACTIVITY OF PYRROLO[3,2-f]QUINAZOLINE-1,3- DIAMINE DERIVATIVES
发明人：AI J LIN; JIAN GUAN; QUAN ZHANG; SKILLMAN DONALD R
权利人:WALTER REED ARMY INST OF RES W; AI J LIN; JIAN GUAN; QUAN ZHANG; SKILLMAN DONALD R
摘要:The invention relates to derivatives of pyrroloquinazolinediamine, more specifically derivatives of 7-(substituted)-7H-pyrrolo[3,2-F] quinazoline-1,3-diamines that are non-toxic and are also effective in the treatment of malaria, including P. falciparum and P.vivax strains. The derivatives are certain carbamate derivatives, succinimide derivatives, alkylcarboxamides derivatives and acetamide derivative, phthalimides, alkylamines and all other amide and imide derivatives and their 1-hydroxy analogs,. The derivatives of the present invention are also soluble in common organic solvents to facilitate the purification in a large scale synthesis of the composition.

专利号:US-8293290-B2
优先权日:2003-04-08
标题:Annatto extract compositions, including geranyl geraniols and methods of use
发明人：TAN BARRIE
权利人:TAN BARRIE; AMERICAN RIVER NUTRITION INC
摘要:Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.

专利号:US-7253177-B2
优先权日:2004-10-22
标 题:Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
发明人：LIN AI J; GUAN JIAN; ZHANG QUAN; SKILLMAN DONALD R
权利人:US ARMY
摘要:The invention relates to derivatives of pyrroloquinazolinediamine, more specifically derivatives of 7-(substituted)-7H-pyrrolo[3,2-F] quinazoline-1,3-diamines that are non-toxic and are also effective in the treatment of malaria, including P. falciparum and P. vivax strains. The derivatives are certain carbamate derivatives, succinimide derivatives, alkylcarboxamides derivatives and acetamide derivative, phthalimides, alkylamines and all other amide and imide derivatives and their 1-hydroxy analogs. The derivatives of the present invention are also soluble in common organic solvents to facilitate the purification in a large scale synthesis of the composition.

专利号:US-8067465-B2
优先权日:2002-01-15
标题:Tricyclic-bis-enone derivatives and methods of use thereof
发明人：HONDA TADASHI; FAVALORO FRANK G; GRIBBLE GORDON W; SPORN MICHAEL B; SUH NANJOO
权利人:HONDA TADASHI; FAVALORO FRANK G; GRIBBLE GORDON W; SPORN MICHAEL B; SUH NANJOO; DARTMOUTH COLLEGE
摘要:Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.

专利号:US-2009234012-A1
优先权日:2002-03-21
标题 :Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
发明人：HINZ MARTIN C
权利人:HINZ MARTIN C
摘要:A method of treating neurotransmitter dysfunction in a patient by optimizing catecholamine levels by administration of L-3,4-dihydroxyphenylalanine (L-Dopa or Dopa) precursors in combination with a source of L-Dopa. The dopa precursor is preferably administered in such quantities such that the amount of dopa from the dopa precursors does not fluctuate and affect outcomes in the synthesis of dopamine from dopa administration. The dopa precursor source is preferably tyrosine, but may alternatively be phenylalanine, N-acetyl-tyrosine, any active isomer thereof, or any other dopa precursor. The source of L-Dopa may include any natural or synthetic source, including, but not limited to, Mucuna pruriens.

专利号:US-7339065-B2
优先权日:2003-07-21
标题 :Design and synthesis of optimized ligands for PPAR
发明人：AVERY MITCHELL A; PERSHADSINGH HARRIHAR A
权利人:BETHESDA PHARMACEUTICALS INC; UNIV MISSISSIPPI
摘要:This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR). The structures of the compounds and methods to design, make and use the compounds are provided. Compounds and methods for administering therapeutic compositions comprising the compounds in cases of the disease psoriasis are provided. An exemplary compound having the formula compound is 5adamantan-2-yl-pentanoic acid {2-[4-(2,4-dioxo-thiazolidin-5-yl-methyl)-phenoxy]-ethyl}-methyl-amide is provided.